B-intervention	0	6	Impact
I-intervention	7	8	+
I-intervention	9	19	resistance
I-intervention	20	28	training
O	29	37	improves
O	38	42	bone
O	43	49	health
O	50	53	and
O	54	58	body
O	59	70	composition
O	71	73	in
B-eligibility	74	85	prematurely
I-eligibility	86	96	menopausal
I-eligibility	97	103	breast
I-eligibility	104	110	cancer
I-eligibility	111	120	survivors
O	120	121	:
O	122	123	a
O	124	134	randomized
O	135	145	controlled
O	146	151	trial
O	151	152	.

O	153	156	Our
O	157	167	randomized
O	168	178	controlled
O	179	184	trial
O	185	187	in
O	188	199	prematurely
O	200	210	menopausal
O	211	217	breast
O	218	224	cancer
O	225	234	survivors
O	235	241	showed
O	242	246	that
O	247	253	impact
O	254	255	+
O	256	266	resistance
O	267	275	training
O	276	285	prevented
O	286	295	increases
O	296	298	in
O	299	309	percentage
O	310	312	of
O	313	317	body
O	318	321	fat
O	322	330	compared
O	331	335	with
O	336	344	controls
O	345	348	and
O	349	353	also
O	354	362	improved
O	363	366	BMD
O	367	369	at
O	370	373	the
O	374	377	hip
O	378	381	and
O	382	391	prevented
O	392	395	BMD
O	396	400	loss
O	401	403	at
O	404	407	the
O	408	413	spine
O	414	419	among
O	420	428	exercise
O	428	429	-
O	429	436	trained
O	437	442	women
O	443	446	who
O	447	451	were
O	452	462	menopausal
O	463	466	for
O	467	468	>
O	468	469	1
O	470	474	year
O	474	475	.

O	476	482	Cancer
O	483	492	treatment
O	492	493	-
O	493	500	related
O	501	510	menopause
O	511	518	worsens
O	519	523	bone
O	524	530	health
O	531	534	and
O	535	539	body
O	540	551	composition
O	552	554	in
O	555	561	breast
O	562	568	cancer
O	569	578	survivors
O	579	580	(
O	580	583	BCS
O	583	584	)
O	584	585	.

O	586	588	We
O	589	601	investigated
O	602	609	whether
O	610	616	impact
O	617	618	+
O	619	629	resistance
O	630	638	training
O	639	644	could
O	645	652	improve
O	653	657	bone
O	658	665	mineral
O	666	673	density
O	674	675	(
O	675	678	BMD
O	678	679	)
O	679	680	,
O	681	687	reduce
O	688	692	bone
O	693	701	turnover
O	701	702	,
O	703	708	build
O	709	715	muscle
O	715	716	,
O	717	720	and
O	721	729	decrease
O	730	733	fat
O	734	738	mass
O	739	741	in
O	742	745	BCS
O	746	750	with
O	751	760	premature
O	761	770	menopause
O	770	771	.

O	772	774	We
O	775	784	conducted
O	785	786	a
O	787	797	randomized
O	798	808	controlled
O	809	814	trial
O	815	817	in
B-total-participants	818	820	71
O	821	824	BCS
O	825	826	(
O	826	830	mean
O	831	834	age
O	834	835	,
B-age	836	838	46
I-age	838	839	.
I-age	839	840	5
I-age	841	846	years
O	846	847	)
O	848	854	within
O	855	856	5
O	857	862	years
O	863	865	of
O	866	875	treatment
O	875	876	-
O	876	883	related
O	884	893	menopause
O	893	894	.

O	895	900	Women
O	901	905	were
O	906	914	randomly
O	915	923	assigned
O	924	926	to
O	927	930	one
O	931	933	of
O	934	937	two
O	938	944	groups
O	944	945	:
O	946	947	(
O	947	948	1
O	948	949	)
O	950	956	impact
O	957	958	+
O	959	969	resistance
O	970	978	training
O	979	980	(
O	980	987	prevent
O	988	1000	osteoporosis
O	1001	1005	with
O	1006	1012	impact
O	1013	1014	+
O	1015	1025	resistance
O	1026	1027	(
O	1027	1032	POWIR
O	1032	1033	)
O	1033	1034	)
O	1035	1037	or
O	1038	1039	(
O	1039	1040	2
O	1040	1041	)
B-control	1042	1050	exercise
I-control	1051	1058	placebo
O	1059	1060	(
O	1060	1064	FLEX
O	1064	1065	)
O	1066	1067	3
O	1067	1068	×
O	1068	1069	/
O	1069	1073	week
O	1074	1077	for
O	1078	1079	1
O	1080	1084	year
O	1084	1085	.

O	1086	1094	Outcomes
O	1095	1099	were
B-outcome-Measure	1100	1103	hip
I-outcome-Measure	1104	1107	and
I-outcome-Measure	1108	1113	spine
I-outcome-Measure	1114	1117	BMD
O	1118	1119	(
O	1119	1121	in
O	1122	1127	grams
O	1128	1131	per
O	1132	1138	square
O	1139	1149	centimeter
O	1149	1150	)
O	1151	1154	and
B-outcome-Measure	1155	1159	body
I-outcome-Measure	1160	1171	composition
O	1172	1173	(
O	1173	1180	percent
O	1181	1185	body
O	1186	1189	fat
O	1190	1191	(
O	1191	1192	%
O	1192	1194	BF
O	1194	1195	)
O	1196	1199	and
B-outcome-Measure	1200	1204	lean
I-outcome-Measure	1205	1208	and
I-outcome-Measure	1209	1212	fat
I-outcome-Measure	1213	1217	mass
O	1218	1219	(
O	1219	1221	in
O	1222	1231	kilograms
O	1231	1232	)
O	1232	1233	)
O	1234	1236	by
O	1237	1240	DXA
O	1241	1244	and
B-outcome-Measure	1245	1249	bone
I-outcome-Measure	1250	1258	turnover
I-outcome-Measure	1259	1266	markers
O	1267	1268	(
O	1268	1273	serum
O	1274	1285	osteocalcin
O	1286	1287	(
O	1287	1289	in
O	1290	1299	nanograms
O	1300	1303	per
O	1304	1314	milliliter
O	1314	1315	)
O	1316	1319	and
B-outcome-Measure	1320	1327	urinary
I-outcome-Measure	1328	1346	deoxypryrodinoline
O	1347	1348	(
O	1348	1350	in
O	1351	1360	nanomoles
O	1361	1364	per
O	1365	1375	milliliter
O	1375	1376	)
O	1376	1377	.

O	1378	1383	There
O	1384	1388	were
O	1389	1391	no
O	1392	1403	significant
B-outcome	1404	1409	group
I-outcome	1410	1411	×
I-outcome	1412	1416	time
I-outcome	1417	1429	interactions
O	1430	1433	for
O	1434	1438	bone
O	1439	1447	outcomes
O	1448	1452	when
O	1453	1458	using
O	1459	1461	an
O	1462	1468	intent
O	1468	1469	-
O	1469	1471	to
O	1471	1472	-
O	1472	1477	treat
O	1478	1486	approach
O	1487	1489	on
O	1490	1493	the
O	1494	1498	full
O	1499	1505	sample
O	1505	1506	.

O	1507	1509	In
O	1510	1518	analyses
O	1519	1529	restricted
O	1530	1532	to
O	1533	1536	BCS
O	1537	1540	who
O	1541	1545	were
O	1546	1556	menopausal
O	1557	1560	for
O	1561	1562	≥
O	1562	1563	1
O	1564	1568	year
O	1568	1569	,
O	1570	1575	POWIR
O	1576	1585	increased
B-outcome	1586	1589	BMD
I-outcome	1590	1592	at
I-outcome	1593	1596	the
I-outcome	1597	1600	hip
O	1601	1604	and
O	1605	1611	slowed
B-outcome	1612	1615	BMD
I-outcome	1616	1620	loss
I-outcome	1621	1623	at
I-outcome	1624	1627	the
I-outcome	1628	1633	spine
O	1634	1642	compared
O	1643	1647	with
O	1648	1652	FLEX
O	1653	1654	(
B-outcome	1654	1661	femoral
I-outcome	1662	1666	neck
I-outcome	1666	1667	-
I-outcome	1667	1672	POWIR
O	1672	1673	,
B-iv-cont-mean	1674	1675	0
I-iv-cont-mean	1675	1676	.
I-iv-cont-mean	1676	1679	004
O	1680	1681	±
B-iv-cont-sd	1682	1683	0
I-iv-cont-sd	1683	1684	.
I-iv-cont-sd	1684	1687	093
I-iv-cont-sd	1688	1689	g
I-iv-cont-sd	1689	1690	/
I-iv-cont-sd	1690	1692	cm
O	1692	1693	(
O	1693	1694	2
O	1694	1695	)
O	1696	1698	vs
O	1698	1699	.
O	1700	1704	FLEX
O	1704	1705	,
B-cv-cont-mean	1706	1707	-
I-cv-cont-mean	1707	1708	0
I-cv-cont-mean	1708	1709	.
I-cv-cont-mean	1709	1712	010
O	1713	1714	±
B-cv-cont-sd	1715	1716	0
I-cv-cont-sd	1716	1717	.
I-cv-cont-sd	1717	1720	089
I-cv-cont-sd	1721	1722	g
I-cv-cont-sd	1722	1723	/
I-cv-cont-sd	1723	1725	cm
O	1725	1726	(
O	1726	1727	2
O	1727	1728	)
O	1728	1729	;
O	1730	1731	p
O	1732	1733	<
O	1734	1735	0
O	1735	1736	.
O	1736	1738	01
O	1738	1739	;
B-outcome	1740	1745	spine
I-outcome	1745	1746	-
I-outcome	1746	1751	POWIR
O	1751	1752	,
B-iv-cont-mean	1753	1754	-
I-iv-cont-mean	1754	1755	0
I-iv-cont-mean	1755	1756	.
I-iv-cont-mean	1756	1759	003
O	1760	1761	±
B-iv-cont-sd	1762	1763	0
I-iv-cont-sd	1763	1764	.
I-iv-cont-sd	1764	1767	114
I-iv-cont-sd	1768	1769	g
I-iv-cont-sd	1769	1770	/
I-iv-cont-sd	1770	1772	cm
O	1772	1773	(
O	1773	1774	2
O	1774	1775	)
O	1776	1778	vs
O	1778	1779	.
O	1780	1784	FLEX
O	1784	1785	,
B-cv-cont-mean	1786	1787	-
I-cv-cont-mean	1787	1788	0
I-cv-cont-mean	1788	1789	.
I-cv-cont-mean	1789	1792	020
O	1793	1794	±
B-cv-cont-sd	1795	1796	0
I-cv-cont-sd	1796	1797	.
I-cv-cont-sd	1797	1800	110
I-cv-cont-sd	1801	1802	g
I-cv-cont-sd	1802	1803	/
I-cv-cont-sd	1803	1805	cm
O	1805	1806	(
O	1806	1807	2
O	1807	1808	)
O	1808	1809	;
O	1810	1811	p
O	1812	1813	=
O	1814	1815	0
O	1815	1816	.
O	1816	1818	03
O	1818	1819	)
O	1819	1820	.

O	1821	1826	POWIR
O	1827	1836	prevented
B-outcome	1837	1846	increases
I-outcome	1847	1849	in
I-outcome	1850	1851	%
I-outcome	1851	1853	BF
O	1854	1855	(
O	1855	1860	POWIR
O	1860	1861	,
B-iv-bin-percent	1862	1863	0
I-iv-bin-percent	1863	1864	.
I-iv-bin-percent	1864	1866	01
I-iv-bin-percent	1867	1868	%
O	1869	1871	vs
O	1871	1872	.
O	1873	1877	FLEX
O	1877	1878	,
B-cv-bin-percent	1879	1880	1
I-cv-bin-percent	1880	1881	.
I-cv-bin-percent	1881	1882	3
I-cv-bin-percent	1883	1884	%
O	1884	1885	;
O	1886	1887	p
O	1888	1889	<
O	1890	1891	0
O	1891	1892	.
O	1892	1894	04
O	1894	1895	)
O	1895	1896	.

O	1897	1902	Women
O	1903	1907	with
O	1908	1918	attendance
O	1919	1921	to
O	1922	1927	POWIR
O	1928	1930	at
O	1931	1932	≥
O	1932	1934	64
O	1935	1936	%
O	1937	1940	had
O	1941	1947	better
B-outcome	1948	1960	improvements
I-outcome	1961	1963	in
I-outcome	1964	1965	%
I-outcome	1965	1967	BF
O	1968	1972	than
O	1973	1978	women
O	1979	1988	attending
O	1989	1993	less
O	1994	1999	often
O	2000	2001	(
O	2001	2002	p
O	2003	2004	<
O	2005	2006	0
O	2006	2007	.
O	2007	2009	03
O	2009	2010	)
O	2010	2011	.

O	2012	2018	Impact
O	2019	2020	+
O	2021	2031	resistance
O	2032	2040	training
O	2041	2044	may
O	2045	2056	effectively
O	2057	2063	combat
O	2064	2068	bone
O	2069	2073	loss
O	2074	2077	and
O	2078	2087	worsening
O	2088	2092	body
O	2093	2104	composition
O	2105	2109	from
O	2110	2119	premature
O	2120	2129	menopause
O	2130	2132	in
O	2133	2136	BCS
O	2136	2137	.
